Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:EQ NASDAQ:FDMT NASDAQ:IMMX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.28+1.1%$4.14$2.12▼$7.55$532.56M1.53.63 million shs468,085 shsEQEquillium$2.17+1.2%$2.00$0.27▼$2.70$138.66M1.67474,259 shs81,625 shsFDMT4D Molecular Therapeutics$9.70-2.4%$9.38$3.00▼$12.34$509.21M2.77750,758 shs128,658 shsIMMXImmix Biopharma$9.61+0.8%$9.34$1.87▼$11.61$510.01M0.12828,183 shs241,635 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics0.00%+3.17%+2.42%+2.92%+55.23%EQEquillium-1.38%+4.90%+11.46%+40.79%+449.99%FDMT4D Molecular Therapeutics-4.70%+11.95%-3.03%+10.46%+218.27%IMMXImmix Biopharma-7.56%+6.83%+4.95%+41.54%+350.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.28+1.1%$4.14$2.12▼$7.55$532.56M1.53.63 million shs468,085 shsEQEquillium$2.17+1.2%$2.00$0.27▼$2.70$138.66M1.67474,259 shs81,625 shsFDMT4D Molecular Therapeutics$9.70-2.4%$9.38$3.00▼$12.34$509.21M2.77750,758 shs128,658 shsIMMXImmix Biopharma$9.61+0.8%$9.34$1.87▼$11.61$510.01M0.12828,183 shs241,635 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics0.00%+3.17%+2.42%+2.92%+55.23%EQEquillium-1.38%+4.90%+11.46%+40.79%+449.99%FDMT4D Molecular Therapeutics-4.70%+11.95%-3.03%+10.46%+218.27%IMMXImmix Biopharma-7.56%+6.83%+4.95%+41.54%+350.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$8.80105.85% UpsideEQEquillium 2.75Moderate Buy$7.67254.12% UpsideFDMT4D Molecular Therapeutics 2.70Moderate Buy$29.88208.15% UpsideIMMXImmix Biopharma 2.50Moderate Buy$18.2589.83% UpsideCurrent Analyst Ratings BreakdownLatest EQ, AQST, FDMT, and IMMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026FDMT4D Molecular Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.004/24/2026AQSTAquestive Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.004/23/2026EQEquillium OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.004/21/2026IMMXImmix Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AQSTAquestive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026FDMT4D Molecular Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026EQEquillium Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/16/2026EQEquillium B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.004/13/2026EQEquillium Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$6.004/7/2026EQEquillium Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$10.003/30/2026FDMT4D Molecular Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $21.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$44.55M11.93N/AN/A($0.28) per share-15.27EQEquillium$41.10M3.33N/AN/A$0.47 per share4.61FDMT4D Molecular Therapeutics$85.21M5.95N/AN/A$8.85 per share1.10IMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$83.78M-$0.78N/AN/AN/A-188.09%N/A-64.46%5/11/2026 (Estimated)EQEquillium-$22.40M-$0.50N/AN/AN/AN/A-119.19%-93.79%5/13/2026 (Estimated)FDMT4D Molecular Therapeutics-$140.11M-$2.42N/AN/AN/A-164.43%-31.75%-28.30%N/AIMMXImmix Biopharma-$29.44M-$0.89N/AN/AN/AN/A-101.25%-73.39%6/3/2026 (Estimated)Latest EQ, AQST, FDMT, and IMMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q1 2026IMMXImmix Biopharma-$0.2084N/AN/AN/AN/AN/A5/13/2026Q1 2026EQEquillium-$0.04N/AN/AN/AN/AN/A5/11/2026Q1 2026AQSTAquestive Therapeutics-$0.14N/AN/AN/A$10.90 millionN/A5/7/2026Q1 2026FDMT4D Molecular Therapeutics-$0.98-$1.01-$0.03-$1.01$2.59 millionN/A5/7/2026Q1 2026IMMXImmix Biopharma-$0.1450-$0.18-$0.0350-$0.18N/AN/A3/25/2026Q4 2025EQEquillium-$0.07-$0.04+$0.03-$0.04N/AN/A3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A3/18/2026Q4 2025FDMT4D Molecular Therapeutics-$0.53$0.43+$0.96$0.43$30.86 million$85.09 million3/4/2026Q4 2025AQSTAquestive Therapeutics-$0.13-$0.26-$0.13-$0.26$13.28 million$13.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A3.143.01EQEquilliumN/A10.5810.58FDMT4D Molecular TherapeuticsN/A9.399.39IMMXImmix BiopharmaN/A10.0110.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%EQEquillium27.05%FDMT4D Molecular Therapeutics99.27%IMMXImmix Biopharma11.26%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics6.81%EQEquillium17.84%FDMT4D Molecular Therapeutics9.60%IMMXImmix Biopharma30.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics160124.29 million115.82 millionOptionableEQEquillium4063.23 million51.95 millionNot OptionableFDMT4D Molecular Therapeutics12052.28 million47.26 millionOptionableIMMXImmix Biopharma953.01 million36.95 millionOptionableEQ, AQST, FDMT, and IMMX HeadlinesRecent News About These CompaniesImmix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings ResultsMay 7 at 10:00 PM | marketbeat.comImmix Biopharma (IMMX) to Release Quarterly Earnings on ThursdayMay 7 at 4:53 AM | marketbeat.comIs Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?May 5 at 5:27 PM | finance.yahoo.comImmix Biopharma, Inc. (NASDAQ:IMMX) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 28, 2026 | marketbeat.comImmix Biopharma (NASDAQ:IMMX) Trading Down 4.6% - Time to Sell?April 16, 2026 | marketbeat.comImmix Biopharma (IMMX) price target increased by 11.73% to 18.62April 9, 2026 | msn.comImmix Biopharma (NASDAQ:IMMX) Trading 12% Higher - Should You Buy?April 9, 2026 | marketbeat.comImmix Biopharma to Participate in the Jefferies Global Healthcare ConferenceApril 9, 2026 | globenewswire.comImmix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming MilestonesMarch 30, 2026 | globenewswire.comMorgan Stanley initiates coverage of Immix Biopharma (IMMX) with overweight recommendationMarch 25, 2026 | msn.comImmix rises as Morgan Stanley starts with bullish view on CAR-T therapyMarch 25, 2026 | msn.comCitizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform RecommendationMarch 10, 2026 | msn.comImmix Biopharma to Participate in Upcoming Investor ConferencesMarch 3, 2026 | globenewswire.comBreakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX)February 13, 2026 | finance.yahoo.comMizuho initiates coverage of Immix Biopharma (IMMX) with outperform recommendationFebruary 10, 2026 | msn.comImmix Biopharma stock climbs after FDA grants breakthrough therapy statusJanuary 29, 2026 | au.investing.comImmix Biopharma Receives Breakthrough Therapy Designation for NXC-201 in Relapsed/Refractory AL Amyloidosis Following Positive Phase 2 ResultsJanuary 28, 2026 | quiverquant.comQImmix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201January 28, 2026 | globenewswire.comImmix Biopharma Announces Positive Phase 2 Trial ResultsDecember 22, 2025 | theglobeandmail.comImmix Biopharma (IMMX) price target increased by 50.00% to 12.24December 21, 2025 | msn.comImmix Biopharma: Thesis Playing Out; Thoughts On Valuation And CompetitionDecember 10, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesASML Falls Post-Earnings, Chip-Making Expansion Anchors OutlookBy Leo Miller | April 16, 2026Could These 3 New-to-Market Quantum Computing Firms Threaten D-Wave?By Nathan Reiff | April 19, 2026Hollywood's New Cash King: Paramount's $24B Power Play By Jeffrey Neal Johnson | April 9, 2026TPG Built a Record Year, Then Lost 40%—Is the Selloff Overdone? By Peter Frank | April 16, 2026Quantum Computing Stocks: Sorting the Real Science from the Hype By Chris Markoch | April 19, 2026EQ, AQST, FDMT, and IMMX Company DescriptionsAquestive Therapeutics NASDAQ:AQST$4.28 +0.05 (+1.06%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Equillium NASDAQ:EQ$2.16 +0.03 (+1.17%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.4D Molecular Therapeutics NASDAQ:FDMT$9.70 -0.24 (-2.37%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Immix Biopharma NASDAQ:IMMX$9.61 +0.07 (+0.78%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
